The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Targeting hyaluronan (HA) in tumor stroma: Interim safety and translational evaluation of pegylated hyaluronidase (PEGPH20) in patients (pts) with advanced solid tumors—A focus on gastrointestinal malignancies.
Jeffrey R. Infante
Consultant or Advisory Role - Halozyme Therapeutics
Ramesh K. Ramanathan
Consultant or Advisory Role - Halozyme Therapeutics
Mitesh J. Borad
Consultant or Advisory Role - Halozyme Therapeutics
Lee S. Rosen
No relevant relationships to disclose
Ronald Korn
Consultant or Advisory Role - Halozyme Therapeutics
Samuel Simon Dychter
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Harold Michael Shepard
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Daniel C. Maneval
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Ping Jiang
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Deborah Carson
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics
Daniel D. Von Hoff
Consultant or Advisory Role - Halozyme Therapeutics
Gregory Ian Frost
Employment or Leadership Position - Halozyme Therapeutics
Stock Ownership - Halozyme Therapeutics